Serum proteomic pattern diagnostics is an emerging paradigm employing low-resolution mass spectrometry (MS) to generate a set of biomarker classifiers. In the present study, we utilized a well-controlled ovarian cancer serum study set to compare the sensitivity and specificity of serum proteomic diagnostic patterns acquired using a high-resolution versus a low-resolution MS platform. In blinded testing sets, the high-resolution mass spectral data contained multiple diagnostic signatures that were superior to the low-resolution spectra in terms of sensitivity and specificity (P<0.00001) throughout the range of modeling conditions. Four mass spectral feature set patterns acquired from data obtained exclusively with the high-resolution mass spectrometer were 100% specific and sensitive in their diagnosis of serum samples as being acquired from either unaffected patients or those suffering from ovarian cancer. Important to the future of proteomic pattern diagnostics is the ability to recognize inferior spectra statistically, so that those resulting from a specific process error are recognized prior to their potentially incorrect (and damaging) diagnosis. To meet this need, we have developed a series of quality-assurance and in-process control procedures to (a) globally evaluate sources of sample variability, (b) identify outlying mass spectra, and (c) develop quality-control release specifications. From these quality-assurance and control (QA/QC) specifications, we identified 32 mass spectra out of the total 248 that showed statistically significant differences from the norm. Hence, 216 of the initial 248 high-resolution mass spectra were determined to be of high quality and were remodeled by pattern-recognition analysis. Again, we obtained four mass spectral feature set patterns that also exhibited 100% sensitivity and specificity in blinded validation tests (68/68 cancer: including 18/18 stage I, and 43/43 healthy). We conclude that (a) the use of high-resolution MS yields superior classification patterns as compared with those obtained with lower resolution instrumentation; (b) although the process error that we discovered did not have a deleterious impact on the present results obtained from proteomic pattern analysis, the major source of spectral variability emanated from mass spectral acquisition, and not bias at the clinical collection site; (c) this variability can be reduced and monitored through the use of QA/QC statistical procedures; (d) multiple and distinct proteomic patterns, comprising low molecular weight biomarkers, detected by high-resolution MS achieve accuracies surpassing individual biomarkers, warranting validation in a large clinical study.

This article has been cited by other articles:

				A. Agarwal, L. Covic, L. M. Sevigny, N. C. Kaneider, K. Lazarides, G. Azabdaftari, S. Sharifi, and A. Kuliopulos Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer Mol. Cancer Ther., September 1, 2008; 7(9): 2746 - 2757. [Abstract] [Full Text] [PDF]

				P. Vineis and F. Perera Molecular Epidemiology and Biomarkers in Etiologic Cancer Research: The New in Light of the Old Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 547 - 567. [Abstract] [Full Text] [PDF]

				D. Jackson, R. A. Craven, R. C. Hutson, I. Graze, P. Lueth, R. P. Tonge, J. L. Hartley, J. A. Nickson, S. J. Rayner, C. Johnston, et al. Proteomic Profiling Identifies Afamin as a Potential Biomarker for Ovarian Cancer Clin. Cancer Res., December 15, 2007; 13(24): 7370 - 7379. [Abstract] [Full Text] [PDF]

				P. Vineis and F. Perera Molecular Epidemiology and Biomarkers in Etiologic Cancer Research: The New in Light of the Old Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1954 - 1965. [Abstract] [Full Text] [PDF]

				Y. V. Karpievitch, E. G. Hill, A. J. Smolka, J. S. Morris, K. R. Coombes, K. A. Baggerly, and J. S. Almeida PrepMS: TOF MS data graphical preprocessing tool Bioinformatics, January 15, 2007; 23(2): 264 - 265. [Abstract] [Full Text] [PDF]

				J. Villanueva, A. J. Martorella, K. Lawlor, J. Philip, M. Fleisher, R. J. Robbins, and P. Tempst Serum Peptidome Patterns That Distinguish Metastatic Thyroid Carcinoma from Cancer-free Controls Are Unbiased by Gender and Age Mol. Cell. Proteomics, October 1, 2006; 5(10): 1840 - 1852. [Abstract] [Full Text] [PDF]

				C. Menard, D. Johann, M. Lowenthal, T. Muanza, M. Sproull, S. Ross, J. Gulley, E. Petricoin, C. N. Coleman, G. Whiteley, et al. Discovering Clinical Biomarkers of Ionizing Radiation Exposure with Serum Proteomic Analysis Cancer Res., February 1, 2006; 66(3): 1844 - 1850. [Abstract] [Full Text] [PDF]

				K. Honda, Y. Hayashida, T. Umaki, T. Okusaka, T. Kosuge, S. Kikuchi, M. Endo, A. Tsuchida, T. Aoki, T. Itoi, et al. Possible Detection of Pancreatic Cancer by Plasma Protein Profiling Cancer Res., November 15, 2005; 65(22): 10613 - 10622. [Abstract] [Full Text] [PDF]

				H. W. Ressom, R. S. Varghese, M. Abdel-Hamid, S. A.-L. Eissa, D. Saha, L. Goldman, E. F. Petricoin, T. P. Conrads, T. D. Veenstra, C. A. Loffredo, et al. Analysis of mass spectral serum profiles for biomarker selection Bioinformatics, November 1, 2005; 21(21): 4039 - 4045. [Abstract] [Full Text] [PDF]

				M. F. Lopez, A. Mikulskis, S. Kuzdzal, D. A. Bennett, J. Kelly, E. Golenko, J. DiCesare, E. Denoyer, W. F. Patton, R. Ediger, et al. High-Resolution Serum Proteomic Profiling of Alzheimer Disease Samples Reveals Disease-Specific, Carrier-Protein-Bound Mass Signatures Clin. Chem., October 1, 2005; 51(10): 1946 - 1954. [Abstract] [Full Text] [PDF]

				R. E. Banks, A. J. Stanley, D. A. Cairns, J. H. Barrett, P. Clarke, D. Thompson, and P. J. Selby Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry Clin. Chem., September 1, 2005; 51(9): 1637 - 1649. [Abstract] [Full Text] [PDF]

				F M Brouwers, E F Petricoin III, L Ksinantova, J Breza, V Rajapakse, S Ross, D Johann, M Mannelli, B L Shulkin, R Kvetnansky, et al. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma Endocr. Relat. Cancer, June 1, 2005; 12(2): 263 - 272. [Abstract] [Full Text] [PDF]

				J. S. Yu, S. Ongarello, R. Fiedler, X. W. Chen, G. Toffolo, C. Cobelli, and Z. Trajanoski Ovarian cancer identification based on dimensionality reduction for high-throughput mass spectrometry data Bioinformatics, May 15, 2005; 21(10): 2200 - 2209. [Abstract] [Full Text] [PDF]

				J. S. Morris, K. R. Coombes, J. Koomen, K. A. Baggerly, and R. Kobayashi Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum Bioinformatics, May 1, 2005; 21(9): 1764 - 1775. [Abstract] [Full Text] [PDF]

				L. A. Liotta, M. Lowenthal, A. Mehta, T. P. Conrads, T. D. Veenstra, D. A. Fishman, and E. F. Petricoin III Importance of Communication Between Producers and Consumers of Publicly Available Experimental Data J Natl Cancer Inst, February 16, 2005; 97(4): 310 - 314. [Abstract] [Full Text] [PDF]

				E. M. Posadas, F. Simpkins, L. A. Liotta, C. MacDonald, and E. C. Kohn Proteomic analysis for the early detection and rational treatment of cancer--realistic hope? Ann. Onc., January 1, 2005; 16(1): 16 - 22. [Abstract] [Full Text] [PDF]

				K. R. Coombes Analysis of Mass Spectrometry Profiles of the Serum Proteome Clin. Chem., January 1, 2005; 51(1): 1 - 2. [Full Text] [PDF]

				K A Baggerly, S R Edmonson, J S Morris, and K R Coombes High-resolution serum proteomic patterns for ovarian cancer detection Endocr. Relat. Cancer, December 1, 2004; 11(4): 583 - 584. [Full Text] [PDF]

				L. A Liotta, E. F Petricoin, T. D Veenstra, and T. P Conrads High-resolution serum proteomic patterns for ovarian cancer detection Endocr. Relat. Cancer, December 1, 2004; 11(4): 585 - 587. [Full Text] [PDF]

				B. A. Wetmore and B. A. Merrick Invited Review: Toxicoproteomics: Proteomics Applied to Toxicology and Pathology Toxicol Pathol, October 1, 2004; 32(6): 619 - 642. [Abstract] [PDF]

				W. E. Grizzle, S. Meleth, E. F. Petricoin, and L. A. Liotta Clarification in the Point/Counterpoint Discussion Related to Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometric Identification of Patients with Adenocarcinomas of the Prostate * Proteomic Pattern Complexity Reveals a Rich and Uncharted Continent of Biomarkers Clin. Chem., August 1, 2004; 50(8): 1475 - 1477. [Full Text] [PDF]